Safety of the extension of use of galacto‐oligosaccharides as a novel food pursuant to Regulation (EU) 2015/2283 Authors: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Margarita Aguilera‐Gómez, Thomas Frenzel, Harry J McArdle, Peter Moldeus, Monika Neuhäuser‐Berthold, Josef Rudolf Schlatter, Henk van Loveren, Emanuela Turla, Domenico Azzollini, Karen Ildico Hirsch‐Ernst Published: 2025 ABSTRACT AbstractFollowing a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto‐oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from milk‐derived lactose using β‐galactosidases. The applicant proposed to extend the use of GOS to several food categories (non‐alcoholic beverages, confectionery, chewing gum, cocoa and chocolate‐based products and protein products). The target population is the general population. GOS is already authorised and included in the Union list of NFs for use in several foods, including infant formula, and in food supplements. The Panel estimated that the proposed extension of use would result in a highest 95th percentile intake of GOS from all food uses, of up to 48.5 g/day in adults. As compared to the exposure to GOS from the currently authorised food uses (at the highest P95), the proposed extension of use is expected to result in an increase in intake of GOS of up to 17%. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS is safe under the proposed conditions of use.Keywords: extension of use, galacto‐oligosaccharides, GOS, novel food INTRODUCTION Background and Terms of Reference as provided by the requestor The Union list set out in the Annex to Implementing Regulation (EU) 2017/2470 1 includes galacto‐oligosaccharide as an authorised novel food. Pursuant to Article 5 of Regulation (EC). No 258/97, 2 galacto‐oligosaccharide has been authorised to be placed on the market as a novel food to be used in a number of foods, including infant formula and follow‐on formula as defined in Regulation (EU) No 609/2013. 3 Commission Implementing Regulation (EU) 2022/684 4 amended the conditions of use of the novel food galacto‐oligosaccharide. In particular, the use of galacto‐oligosaccharide has been extended to additional foods namely, dairy confectionery, cheese and processed cheese, butter and spreadable fats. Commission Implementing Regulation (EU) 2024/1027 5 amended the specifications of the novel food galacto‐oligosaccharide. In particular, galactose has been removed from the specifications. On 21 March 2025, the company ‘FrieslandCampina Ingredients’ submitted a request to the European Commission in accordance with Article 10 of Regulation (EU) 2015/2283 to request a change in the conditions of use of the novel food galacto‐oligosaccharide. The current application proposes to extend the current conditions of use of galacto‐oligosaccharide to include non‐alcoholic beverages, confectionery, chewing gum, cocoa and chocolate‐based products and protein products. The applicant has requested data protection under Article 26 of Regulation (EU) 2015/2283 for data in support of this request. In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission requests the European Food Safety Authority to provide a scientific opinion on a change in the conditions of use of the novel food galacto‐oligosaccharides. In this opinion, the European Food Safety Authority should also document whether and to what extent the requirements of Article 26(2)(c) of Regulation (EU) 2015/2283 are fulfilled regarding the data for which the applicant is requesting data protection. Additional information On 17 December 2020, EFSA adopted an opinion on a change in the conditions of use of GOS in food supplements (EFSA NDA Panel, 2021a). The panel concluded that the NF was safe under the proposed extension of use. On 14 September 2021, EFSA adopted an opinion on the extension of use of GOS as an ingredient in other food categories (dairy confectionery, cheese and processed cheese, butter and spreads) (EFSA NDA Panel, 2021b). The panel concluded that the NF was safe under the proposed extension of use. On 28 February 2022, EFSA adopted an opinion on a change in the conditions of use in food for special medical purposes (EFSA NDA Panel, 2022). The panel concluded that the NF was safe under the proposed conditions of use. DATA AND METHODOLOGIES Data The safety assessment of this NF is based on data supplied in the application and additional data identified by the panel. Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation (EU) 2015/2283 are listed in Commission Implementing Regulation (EU) 2017/2469. 6 A common and structured format on the presentation of NF applications is described in the EFSA guidance on the preparation and presentation of an NF application (EFSA NDA Panel, 2021c). As indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary, confidential and published) scientific data (including both data in favour and not in favour) that are pertinent to the safety of the NF. The applicant has submitted a confidential and a non‐confidential version of a dossier following the ‘EFSA guidelines on the preparation and presentation of a NF application’ (EFSA NDA Panel, 2021c) and the ‘Administrative guidance for the preparation of applications on novel foods pursuant to Article 10 of Regulation (EU) 2015/2283’ (EFSA, 2021). In accordance with Art. 38 of Regulation (EC) No 178/2002 7 and taking into account the protection of confidential information and of personal data in accordance with Articles 39–39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality, 8 the non‐confidential version of the dossier has been published on Open.EFSA. 9 According to Art. 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre‐submission phase and public consultations, EFSA carried out a public consultation on the non‐confidential version of the technical dossier from 16 September 2025 to 7 October 2025 for which no comments were received. This NF application includes a request for protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/2283. The data requested by the applicant to be protected consist of the certificates of analysis (Annex A in the compositional data). Methodologies The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA Panel, 2021c) and the principles described in the relevant existing guidance documents from the EFSA Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and in Article 7 of Commission Implementing Regulation (EU) 2017/2469. This assessment concerns only the risks that might be associated with the consumption of the NF under the proposed conditions of use and is not an assessment of the efficacy of the NF with regard to any claimed benefit. In the context of this opinion, EFSA's definition of dietary fibre (i.e. non‐digestible carbohydrates plus lignin; EFSA NDA Panel, 2010) does not reflect the additional requirement of having a beneficial physiological effect demonstrated by generally accepted scientific evidence laid down in Annex I of Regulation (EC) 1169/2011 10 for: edible carbohydrate polymers which have been obtained from food raw material by physical, enzymatic or chemical means, and edible carbohydrate polymers which have been obtained from food raw material by physical, enzymatic or chemical means, and edible synthetic carbohydrate polymers. edible synthetic carbohydrate polymers. It is out of the scope of this opinion to establish whether the fraction of non‐digestible carbohydrates present in the NF meets the legal definition of dietary fibre in the EU or not. ASSESSMENT Introduction This opinion addressed the applicant's request to extend the use of the NF as a food ingredient in additional food categories (non‐alcoholic beverages, confectionery, chewing gum, cocoa and chocolate products and protein products). Identity of the NF The NF, which is the subject of this request for extension of use, is mainly composed of galacto‐oligosaccharides (GOS). GOS are oligosaccharides containing 2–9 galactosyl units linked to a terminal glucose via β‐glycosidic bonds such as β (1 → 2), β (1 → 3), β (1 → 4) or β (1 → 6). GOS are considered dietary fibre, in accordance with the definition that encompasses non‐digestible carbohydrates (EFSA NDA Panel, 2010). The NF is produced from milk‐derived lactose by an enzymatic process using β‐galactosidases from microorganisms as specified in the Union list. The applicant stated that no changes have been introduced in the production process as defined in Commission Implementing Regulation (EU) 2017/2470. 11 Compositional data The applicant provided the analysis of five batches of the NF (Table 1) which demonstrates that the NF meets the specification as reported in the Union list. TABLE 1Analysis of five batches of the NF.Parameter (unit)Batch numberMethod of analysis#1#2#3#4#5GOS (% DM)73.274.274.274.075.3FC method using modified AOAC Method 2001.02, HPAEC‐PADLactose (% DM)20.620.620.620.818.6FC method using modified AOAC Method 2001.02, HPAEC‐PADGlucose (% DM)6.25.24.15.25.2FC method using modified AOAC Method 2001.02, HPAEC‐PADAsh (% DM)0.10.10.10.10.1FC method equivalent to NEN‐ISO 5809Protein (% DM)< 0.265< 0.265< 0.265< 0.265< 0.265Calculation (N x 6.25)Nitrite mg/kg< 1< 1< 1< 1< 1ISO 14673‐2/IDF 189‐2Abbreviations: AOAC, Association of Official Analytical Collaboration; DM, dry matter; FC, FrieslandCampina; GOS, galacto‐oligosaccharides; HPAEC‐PAD, high‐performance anion exchange chromatography with pulsed amperometric detection; IDF, International Dairy Federation; ISO, International Organization for Standardization; N, nitrogen; NEN, Nederlandse Norm (standard accepted in the Netherlands). Analysis of five batches of the NF. Abbreviations: AOAC, Association of Official Analytical Collaboration; DM, dry matter; FC, FrieslandCampina; GOS, galacto‐oligosaccharides; HPAEC‐PAD, high‐performance anion exchange chromatography with pulsed amperometric detection; IDF, International Dairy Federation; ISO, International Organization for Standardization; N, nitrogen; NEN, Nederlandse Norm (standard accepted in the Netherlands). Specifications The applicant confirmed that no changes have been introduced in the specifications. The specifications of the NF, as reported in the Union list, 12 are indicated in Table 2. TABLE 2Specifications of the NF (as authorised). Description: Galacto‐oligosaccharide is produced from milk lactose by an enzymatic process using β‐galactosidases from Aspergillus oryzae, Bifidobacterium bifidum, Pichia pastoris, Sporobolomyces singularis, Kluyveromyces lactis and Papiliotrema terrestris Parameter Specification GOSmin. 46% dry matter (DM)Lactosemax. 40% DMGlucosemax. 22% DMAshmax. 4.0% DMProteinmax. 4.5% DMNitritemax. 2 mg/kg Specifications of the NF (as authorised). History of use of the NF and/or of its source History of use of the source As previously reported by EFSA (EFSA NDA Panel, 2021a, 2021b, 2022), GOS are naturally occurring in milk‐based products. Fermented milk products (such as yoghurts) can contain a significant amount of GOS due to the enzymatic activity of microbial β‐galactosidases on lactose (Toba et al., 1982; Villaluenga‐Martinez et al., 2008). Lactose‐free milks can also contain GOS as a result of lactose hydrolysis (Ruiz‐Matute et al., 2012). History of use of the NF GOS have been authorised 13 to be placed on the EU market as NF to be used in a number of foods (e.g. milk drinks, yoghurt, dairy desserts, cereals, cheese), food supplements, baby foods, infant formula and follow‐on formula. As previously reported by EFSA (EFSA NDA Panel, 2021a, 2021b, 2022), GOS are permitted for use in foods, food supplements, infant formulae in several countries (e.g. Australia, New Zealand, the United States). Proposed uses and use levels and anticipated intake Target population The target population proposed by the applicant is the general population. Proposed uses and use levels The applicant proposed to extend the use of the NF as an ingredient in non‐alcoholic beverages, confectionery, chewing gum, cocoa and chocolate products and protein products. The proposed new uses, categorised according to the FoodEx2 14 hierarchy, along with the corresponding maximum use levels, are detailed in Table 3. For the new intended use in protein products, which are not explicitly coded in the FoodEx2 hierarchy, the applicant has identified suitable surrogate food categories, namely ‘cereal bars’ and ‘whey powder’. The proposed maximum use levels are expressed as mg GOS/100 g final product. TABLE 3New intended uses and maximum use levels of the NF proposed by the applicant.FoodEx2 levelFoodEx2 codeFood categoryMax use level (mg GOS/100 g)3A00EYCereal bars a 12,5003A033RSyrups (molasses and other syrups)25,0003A03HECocoa ingredients50003A03KYCocoa beverages20003A046HChocolate sauce50003A046JFudge sauce50003A0ETVFruit/vegetable juice concentrate21004A02MPFlavoured milks20004A02PNWhey powder a , b 25,0004A03DYFlavoured bottled water20004A03FQCola‐type drinks18504A03GCFortified bottled water20004A03GELiquid drink bases (including concentrates and home‐made preparations)10,0004A03GFPowdered drink bases25,0004A03HHCocoa beverage preparation, powder10,0004A03KKIced coffee18255A034JMilk chocolate22505A034RChocolate‐coated confectionery22505A035KGum drops10,0005A035LJelly candies10,0005A035MChewing gum10,000 a No available codes in DietEx for protein products; therefore, cereal bars and whey powder were considered suitable surrogates. b The intended uses also include protein drinks. New intended uses and maximum use levels of the NF proposed by the applicant. No available codes in DietEx for protein products; therefore, cereal bars and whey powder were considered suitable surrogates. The intended uses also include protein drinks. Anticipated intake of the NF (authorised uses and new intended uses) EFSA estimated the anticipated daily intake of the NF (expressed as GOS) of the currently authorised uses, which have been translated into FoodEx2 categories (Appendix A). The lowest and highest mean and 95th percentile anticipated daily intake of the NF (on a g/day basis, expressed as GOS) among the EU dietary surveys are presented in Table 4. TABLE 4Intake estimate of the NF resulting from the use as an ingredient in the currently authorised uses (expressed as g GOS/day).Population groupAge (years)Mean intake (g/day)P95 intake (g/day)Lowest a Highest a Lowest b Highest b Infants< 12.98.86.927.3Young children c 1 to < 39.518.017.432.1Other children3 to < 1010.119.521.033.2Adolescents10 to < 188.023.120.242.4Adults d ≥ 187.720.519.643.2 Note: P95, 95th percentile of the intake distribution. a Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and highest averages observed among all EU surveys are reported in these columns. b Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and the highest P95 observed among all EU surveys are reported in these columns (P95 based on fewer than 60 individuals are not considered). c Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011). d Includes elderly, very elderly, pregnant and lactating women, vegetarians. Intake estimate of the NF resulting from the use as an ingredient in the currently authorised uses (expressed as g GOS/day). Note: P95, 95th percentile of the intake distribution. Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and highest averages observed among all EU surveys are reported in these columns. Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and the highest P95 observed among all EU surveys are reported in these columns (P95 based on fewer than 60 individuals are not considered). Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011). Includes elderly, very elderly, pregnant and lactating women, vegetarians. The applicant estimated the anticipated daily intake of the NF (expressed as GOS) based on the new intended uses (Table 3) and the authorised uses, which have been translated into FoodEx2 categories (Appendix A). The anticipated daily intake, which was confirmed by EFSA, was estimated using the EFSA Dietary Exposure (DietEx) Tool, 15 which is based on individual data from the EFSA Comprehensive European Food Consumption Database (EFSA, 2011). The lowest and highest means and 95th percentiles anticipated daily intake of the NF (on a g/day basis, expressed as GOS), among the EU dietary surveys, are presented in Table 5. TABLE 5Intake estimate of the NF resulting from the use as an ingredient in the new intended uses and the currently authorised uses (expressed as g GOS/day).Population groupAge (years)Mean intake (g/day)P95 intake (g/day)Lowest a Highest a Lowest b Highest b Infants< 13.98.99.227.3Young children c 1 to < 39.618.718.332.1Other children3 to < 1010.622.921.539.0Adolescents10 to < 189.625.421.247.3Adults d ≥ 188.523.621.148.5Abbreviation: P95, 95th percentile. a Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and highest averages observed among all EU surveys are reported in these columns. b Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and the highest P95 observed among all EU surveys are reported in these columns (P95 based on less than 60 individuals is not considered). c Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011). d Includes elderly, very elderly, pregnant and lactating women, vegetarians. Intake estimate of the NF resulting from the use as an ingredient in the new intended uses and the currently authorised uses (expressed as g GOS/day). Abbreviation: P95, 95th percentile. Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and highest averages observed among all EU surveys are reported in these columns. Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 07/10/2025. The lowest and the highest P95 observed among all EU surveys are reported in these columns (P95 based on less than 60 individuals is not considered). Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011). Includes elderly, very elderly, pregnant and lactating women, vegetarians. The estimated daily intake expressed on a mg/kg body weight per day and on a mg/day basis, for each population group, from each EU dietary survey, is available in the Excel file annexed to this scientific opinion (Annex A under supporting information). Considering the highest 95th percentile of anticipated intake as presented in Table 5, the proposed extension of use is expected to result in an increase in intake of GOS of up to 17% (in other children) compared to the highest 95th percentile of anticipated intake from the currently authorised food uses. The NF is also authorised for use in food supplements, at a maximum daily intake of 16.2 g of GOS, for individuals aged 3 years and above. The exposure to GOS from the combined intake of the NF from the uses as ingredient (new and authorised uses at the highest P95) and food supplements ranges from 55 g GOS per day to 65 g GOS per day. The Panel considers that it is very unlikely that individuals consuming high amounts of GOS in foods would simultaneously consume food supplements containing the NF. Furthermore, high intakes of fermentable fibres such as GOS may induce gastrointestinal symptoms which limit their acceptability and intake (see Section 3.7). Nutritional information GOS are a type of dietary fibre. The term dietary fibre collectively describes non‐digestible carbohydrates that are resistant to hydrolysis and absorption in the small intestine and enter the colon substantially unmodified. Non‐starch polysaccharides, the main constituents of dietary fibre, are heterogeneous in their chemical composition and physicochemical properties (e.g. solubility, viscosity, fermentability), characteristics that determine their functional (e.g. laxation) and undesirable (e.g. bloating, flatulence, borborygmi/rumbling) gastrointestinal (GI) effects (EFSA NDA Panel, 2010). Supplemental intakes of dietary fibre (i.e. added to foods or consumed as food supplements) may lead to undesirable GI symptoms, but the amount of supplemental fibre at which these effects occur highly depends on the type of fibre (e.g. the extent to which it is fermented in the colon), the pattern of consumption (e.g. as a single dose or throughout the day), and host factors (e.g. diet, intestinal microbiota composition, genetics and health status), with high interindividual variability. Inulin‐type fructans (ITFs) and GOS, as fermentable fibres, can induce flatulence and bloating. Supplemental intakes of GOS of 20 g/day have been shown to be well tolerated by healthy adults in human intervention studies (Mysonhimer & Holscher, 2022). Tolerance to supplemental fermentable fibre has been shown to increase over time, whereas the persistence of undesirable GI effects limits acceptability, and thus intake (Dinleyici et al., 2025; Holscher et al., 2022). No tolerable upper intake level (UL) for dietary fibre, or for a specific type of fibre, has been set. Adequate intakes (AI) for dietary fibre in mixed diets, but not for specific fibre types, have been established for all population groups (except infants) based on bowel function (i.e. laxation) (EFSA NDA Panel, 2010). Average intakes of dietary fibre in most adult populations and in half of the child population in Europe are below the AI for the respective age group (EFSA NDA Panel, 2022). It is estimated that a breastfed infant would consume between 4 and 12 g/day of non‐digestible oligosaccharides during the first half year of life. The addition of non‐digestible oligosaccharides to infant formula and follow‐on formula is regulated as in Commission Delegated Regulation (EU) 2016/127. 16 The panel does not expect that the proposed new uses of this non‐digestible oligosaccharide are nutritionally disadvantageous. Toxicological information The applicant conducted a comprehensive literature search (dated: January 2025) to identify new studies (published after the EFSA safety assessment in 2021a) on GOS. The full search strategy, databases and results were provided. No new genotoxicity, toxicity (subchronic, chronic toxicity and carcinogenicity), reproductive and developmental toxicity studies were identified. Human data The literature search provided by the applicant identified human intervention studies with GOS which were published since the last EFSA opinion (EFSA NDA Panel, 2021a). Two studies were conducted in infants. Preterm infants were administered GOS via infant formula (GOS supplemented formula not characterised) for up to 28 days, and no adverse events were reported (Utomo et al., 2021). In healthy term infants, the administration of a short‐chain GOS and long‐chain FOS mix (9:1 ratio) at 0.4 g/100 mL of infant formula for 3 months and at 0.03 g/g of infant formula for 11 months was well tolerated (Bellaiche et al., 2023; Piloquet et al., 2024). The applicant identified four human intervention studies in adults, two of which were not considered further: one study (Schaafsma et al., 2022) was available only as an abstract, while the other (Buhaș et al., 2023) used a GOS/FOS/XOS mixture in combination with a mixture of five bacterial strains as compared to no intervention, so that the design did not allow drawing conclusions about the effects of GOS alone on the endpoints measured. The characteristics of the remaining two studies identified by the applicant (Angima et al., 2025; Azcarate‐Peril et al., 2017) and of two additional studies identified by EFSA (Looijesteijn et al., 2024; Schoemaker et al., 2022) are briefly described below. These four intervention studies investigated the effects of GOS supplementation in adult populations. Azcarate‐Peril et al. (2017) conducted a randomised, double‐blind, placebo‐controlled trial in which 85 lactose‐intolerant subjects were randomised (2:1 ratio) to receive either increasing doses of purified GOS (RP‐G28, > 95% purity) from 1.5 to 15 g/day over 36 days, or placebo, followed by a 30‐day dairy reintroduction period. Schoemaker et al. (2022) randomised 132 adults (18–59 years) with self‐reported constipation to consume either 5.5 g (n = 45) or 11 g (n = 44) of GOS daily, or maltodextrin (n = 43; control), for 3 weeks. Looijesteijn et al. (2024) examined the effects of daily supplementation with 1.3 g (n = 44) or 2.0 g GOS (n = 44) for 3 weeks in 88 healthy women (42–70 years), following a 3‐week control period. GOS were consumed as a single daily dose in these three studies. Angima et al. (2025) provided 14 lactose‐intolerant adults with either 5.2 g of GOS powder twice daily (n = 7), resulting in a total daily intake of 7.6 g GOS and 2.2 g lactose, or 1 g lactose (n = 7, control) for 3 weeks, followed by a 3‐week washout period. In these four studies, GOS supplementation was generally well tolerated with no serious adverse events reported, though mild and transient gastrointestinal symptoms such as bloating were occasionally noted. The panel notes that these studies in adults have tested daily doses of GOS below the anticipated intakes of the NF under the proposed uses and use levels, and that no studies in children have become available. The panel also notes that human intervention studies using higher supplemental daily doses of GOS have shown good tolerance in adults at 20 g/day (Section 3.7). No adverse effects other than undesirable GI symptoms have been reported at higher doses. DISCUSSION The NF is mainly composed of GOS and it is produced from milk‐derived lactose by an enzymatic process. GOS are considered dietary fibre, in accordance with the definition that encompasses non‐digestible carbohydrates. GOS is authorised as NF to be used in a number of foods, food supplements and infant formula and follow‐on formula. This opinion addresses the applicant's request to extend the use of the NF as a food ingredient in additional food categories (non‐alcoholic beverages, confectionery, chewing gum, cocoa and chocolate products and protein products). As compared to the exposure to GOS from the currently authorised food uses (at the highest P95), the proposed extension of use is expected to result in an increase in intake of GOS of up to 17%. No UL for dietary fibre, or for a specific type of fibre, has been set (EFSA NDA Panel, 2010) and, apart from undesirable gastrointestinal effects (e.g. bloating, flatulence, borborygmi/rumbling), which in general may be related to high intakes of fermentable fibre, no other adverse effects have been reported. The occurrence of such gastrointestinal symptoms related to the intake of fermentable fibre differs among individuals and may limit its intake. The other constituents present in the NF (e.g. lactose, glucose) are normal components of the habitual diet. The panel considers that the proposed extension of the use of NF, mainly composed of galacto‐oligosaccharides, in additional food categories does not raise safety concerns. CONCLUSION The panel concludes that the NF, mainly composed of galacto‐oligosaccharides, is safe under the proposed extension of use. Protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/2283 The panel could have reached the conclusion on the safety of the NF under the proposed conditions of use without the data claimed as proprietary by the applicant (Appendix B). ABBREVIATIONS adequate intake body weight Dietary Exposure (tool) dry matter Fructo‐oligosaccharides gastrointestinal galacto‐oligosaccharides Nutrition, Novel Foods and Food Allergens novel food tolerable upper intake level xylo‐oligosaccharides REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2025‐00229 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani and Frank Thies. Supporting information ANNEX A: Estimates of dietary exposure to the Novel Food for each population group from each EU dietary survey Authorised uses of the NF (as ingredient) translated into FoodEx2 categories FoodEx codeFoodEx nameMax use level (mg GOS/100 g)A00BZFruit pie‐tarts12,500A00ELMixed breakfast cereals12,500A00EYCereal bars12,500A01QJFruit or fruit–vegetable puree12,500A01QPFruit preparations for fillings and/or flavouring5900A02LVCow milk2000A02MBGoat milk2000A02MCSheep milk2000A02MVButtermilk2000A02NEYoghurt3700A02NQYoghurt drinks, including sweetened and/or flavoured variants3700A02NRProbiotic milk‐like drinks3700A02PTDairy dessert and similar4300A02QECheese10,000A039CButter10,000A03GAEnergy drinks2100A03GBIsotonic and sport drinks4400A03PZInfant formulae, powder6400A03QEInfant formulae, liquid800A03QKFollow‐on formulae, powder6400A03QQFollow‐on formulae, liquid800A03QYSimple cereals which have to be reconstituted with milk or other appropriate nutritious liquids18,900A03RABiscuits, rusks and cookies for children2700A03REReady‐to‐eat cereal‐based meal for children14,300A03RHReady‐to‐eat dairy‐based meal for children2400A03RLOther food for infants and children2500A03THMilk imitates2000A0BX9Fruit/vegetable juices and nectars2100A0BZESimple cereals for infants or children, reconstituted2700A0CXAEuropean buffalo milk2000A0EQNSoft drinks with minor amounts of fruits or flavours2100A0F1GMargarines and similar10,000 List of elements of the dossier for which data protection was requested NF sectionElements of the application dossier for which a request for data protection was filed by the applicantFile considered as pertinent for the NDA panel to reach the conclusion on the safety (yes/no)Compositional dataCertificates of analysis (Annex A in the compositional data)No Estimates of dietary exposure to the Novel Food for each population group from each EU dietary survey This Annex is available under the Supporting Information section of the online version of this output. EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) , Turck, D. , Bohn, T. , Cámara, M. , Castenmiller, J. , De Henauw, S. , Jos, Á. , Maciuk, A. , Mangelsdorf, I. , McNulty, B. , Naska, A. , Pentieva, K. , Siani, A. , Thies, F. , Aguilera‐Gómez, M. , Frenzel, T. , McArdle, H. J. , Moldeus, P. , Neuhäuser‐Berthold, M. , … Hirsch‐Ernst, K. I. (2025). Safety of the extension of use of galacto‐oligosaccharides as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 23(12), e9797. 10.2903/j.efsa.2025.9797 Adopted: 19 November 2025 Correspondence: Ask a Question The declarations of interest of all scientific experts active in EFSA's work are available at https://open.efsa.europa.eu/experts. Notes Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72, ELI: http://data.europa.eu/eli/reg_impl/2017/2470/oj). Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel foods ingredients (OJ L 43, 14.2.1997, p. 1, ELI: http://data.europa.eu/eli/reg/1997/258/oj). Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 (OJ L 181, 29.6.2013, p. 35, ELI: http://data.europa.eu/eli/reg/2013/609/oj). Commission Implementing Regulation (EU) 2022/684 of 28 April 2022 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food galacto‐oligosaccharide (OJ L 126, 29.4.2022, p. 10, ELI: http://data.europa.eu/eli/reg_impl/2022/684/oj). Commission Implementing Regulation (EU) 2024/1027 of 8 April 2024 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food galacto‐oligosaccharide (OJ L, 2024/1027, 9.4.2024, ELI: http://data.europa.eu/eli/reg_impl/2024/1027/oj). Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, pp. 1–48. Decision available at: https://www.efsa.europa.eu/en/corporate‐pubs/transparency‐regulation‐practical‐arrangements. The non‐confidential version of the dossier has been published on Open.EFSA and is available at the following link: https://open.efsa.europa.eu/questions/EFSA‐Q‐2025‐00229. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 Text with EEA relevance. Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72, ELI: http://data.europa.eu/eli/reg_impl/2017/2470/oj). Commission Implementing Regulation (EU) 2024/1027 of 8 April 2024 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food galacto‐oligosaccharide. Official Journal of the European Union, L series, 9.4.2024. Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351, 30.12.2017, pp. 72–201. FoodEx2 is an EFSA standardised food classification and description system https://www.efsa.europa.eu/en/data/data‐standardisation. https://www.efsa.europa.eu/it/science/tools‐and‐resources/dietex. Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for infant formula and follow‐on formula and as regards requirements on information relating to infant and young child feeding. REFERENCES Associated Data Supplementary Materials ANNEX A: Estimates of dietary exposure to the Novel Food for each population group from each EU dietary survey